Skip to main content
OpenTrials

Clinical trial condition

Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Explore clinical trials studying Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL). Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies
Refine in advanced search Browse all conditions

Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) trial results

Completed

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

NCT02315326

Conditions
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Disease Attributes, Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL), +3 more
Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack (Limited Protocol Activities) Commack, New York, United States
View Trial Details

Related conditions